Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
52 Week high
52 Week low
InvestorPlace • 3 days ago • EXEL3 Biotech Stocks That Should Be on Every Investor's Radar This Fall
Zacks Investment Research • 10 days ago • EXELExelixis (EXEL) Gets Rights for Tumor Candidate From Insilico
Market Watch • 11 days ago • EXELExelixis to license Insilico AI-designed cancer drug
Zacks Investment Research • 18 days ago • EXELEXEL vs. ILMN: Which Stock Is the Better Value Option?
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.